After weeks of steady progress on GLP-1 receptor agonists (like Ozempic® or Wegovy®) or dual GIP/GLP-1 co-agonists (like Mounjaro®), the scale frequently pauses. In metabolic endocrinology, this equilibrium is called a weight-loss plateau—a normal evolutionary adaptation of the human body.
Understanding Adaptive Thermogenesis
As body mass drops, your Resting Metabolic Rate (RMR) recalibrates: an individual at 170 lbs expends fewer daily calories for baseline functions than when at 210 lbs. Simultaneously, adipocytes down-regulate leptin secretion, which can subtly elevate background appetite.
4 Evidence-Based Adjustments to Discuss with Your Doctor
- Audit Daily Protein Intake (0.6g to 0.8g/lb or 1.2–1.6g/kg): Early satiety often causes patients to eat less protein, which accelerates muscle loss and lowers basal metabolic rate.
- Enforce Anatomical Injection Rotation: Injecting repeatedly in the same spot can cause subtle lipohypertrophy, blunting drug bioavailability.
- Screen for Water Retention & Constipation: Sluggish bowel motility can store 2–4 lbs of water and intestinal waste, masking actual body fat reduction.
- Consult on Dose Escalation: If you have completed at least 4 weeks on your current dosage and the stall lasts over a month, your physician will evaluate whether a titration step is indicated.
